Cargando…
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making
Dose-adjusted-EPOCH-R obviates the need for radiotherapy in most patients with primary mediastinal B-cell lymphoma. End-of-treatment PET, however, does not accurately identify patients at risk of treatment failure, thereby confounding clinical decision making. To define the role of PET in primary me...
Autores principales: | Melani, Christopher, Advani, Ranjana, Roschewski, Mark, Walters, Kelsey M., Chen, Clara C., Baratto, Lucia, Ahlman, Mark A., Miljkovic, Milos D., Steinberg, Seth M., Lam, Jessica, Shovlin, Margaret, Dunleavy, Kieron, Pittaluga, Stefania, Jaffe, Elaine S., Wilson, Wyndham H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068044/ https://www.ncbi.nlm.nih.gov/pubmed/29748435 http://dx.doi.org/10.3324/haematol.2018.192492 |
Ejemplares similares
-
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
por: Lakhotia, Rahul, et al.
Publicado: (2023) -
Next-generation sequencing–based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL
por: Miljkovic, Milos D., et al.
Publicado: (2021) -
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma
por: Lakhotia, Rahul, et al.
Publicado: (2022) -
Good outcome of AIDS-related Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with abbreviated cycles of EPOCH-rituximab
por: Dunleavy, K, et al.
Publicado: (2009) -
Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment
por: Lai, Catherine, et al.
Publicado: (2022)